U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524777) titled 'Ganoderma Spores Modulate the Gut-Brain Axis' on April 01.
Brief Summary: This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 >= 8). Participants will be randomly assigned(2 : 1) to receive RGLS (2 g/day) or matched placebo.
Study Start Date: April 15
Study Type: INTERVENTION...